Robert Ang, M.D., M.B.A.
Robert Ang is Neon’s chief business officer. Prior to Neon, Robert served as senior vice president of business development at Bavarian Nordic, an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. In this role, Robert was primarily responsible for conducting the transaction between Bavarian Nordic and Bristol-Myers Squibb for PROSTVAC, a Phase 3 immuno-oncology asset, in a landmark $975M deal completed in March 2015.
Prior to joining Bavarian Nordic, Robert served as both head of business development and medical affairs for Cadence Pharmaceuticals and, prior to that, Robert worked at Frazier Healthcare Ventures, a leading health care venture capital firm. At Frazier, he led two investment rounds in Cadence Pharmaceuticals alongside other investments in pharmaceuticals and biotechnology, including Incline Therapeutics (now The Medicines Company), Alnara Pharmaceuticals (now Eli Lilly) and Collegium Pharmaceuticals (which spun out PreCision Dermatology, now Valeant Pharmaceuticals). Robert also has experience in management consulting with the Boston Consulting Group and general surgical residency training.
Robert holds an M.B.B.S. (Doctor of Medicine) from the University of Western Australia and an MBA, with honors, from Columbia Business School.